PReDicT Antidepressant Algorithm Cost-Effectiveness Was Uncertain
A 913-person economic evaluation of the PReDicT antidepressant algorithm found nearly identical EQ-5D quality-of-life gains vs. treatment as usual (+0.139 vs. +0.140) and nearly identical societal cost reductions (−€2,589 vs. −€2,602), while cost-effectiveness probabilities were only 46% to 59% at trial level but exceeded 80% in the UK.1 The algorithm signal was country-specific and capability-weighted, …